{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041417","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.760558+00:00","generated_at":"2026-06-11T19:15:44.693678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProKidney reports Q2 2023 net loss of $34.8M; cash at $446.1M","bullets":["Net loss before noncontrolling interest $34.8M for Q2 2023 vs $22.1M in Q2 2022.","R&D expenses $26.4M (up from $11.6M) driven by Phase 3 trial and manufacturing expansion.","Cash, equivalents and marketable securities $446.1M as of June 30, 2023, down from $490.3M at Dec 31, 2022.","Purchased 210,000 sq ft Greensboro facility; $458M investment planned by 2027 with $33.7M in tax incentives.","Phase 3 proact 1 enrolling; interim data expected end 2024; proact 2 enrollment expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041417","json":"https://secwatch.observer/filing/0000950170-23-041417.json","markdown":"https://secwatch.observer/filing/0000950170-23-041417.md","text":"https://secwatch.observer/filing/0000950170-23-041417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/0000950170-23-041417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/prok-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:15:44.693678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33c906e4362061440c651077e7b6977f86567849","claim":"PROKIDNEY CORP. reported second quarter ended June 30, 2023 results: net income Net loss before noncontrolling interest was $34.8 million.","evidence_excerpt":"ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/0000950170-23-041417-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss before noncontrolling interest was $34.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}